Novan

    OverviewSuggest Edit

    Novan is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. It develops NITRICIL technology that allows the control of the level of nitric oxide storage, the rate of release, and the molecule size for targeted delivery.
    TypePrivate
    Founded2008
    HQNC, US
    Websitenovan.com
    Employee Ratings2.2

    Latest Updates

    Employees (est.) (May 2021)41(-4%)
    Share Price (May 2021)$1.1(-3%)
    Cybersecurity ratingBMore

    Key People/Management at Novan

    Carri Geer

    Carri Geer

    SVP, Chief Technology Officer
    John M. Gay

    John M. Gay

    Chief Financial Officer
    W. Kent Geer

    W. Kent Geer

    Lead Independent Director
    Paula Brown Stafford

    Paula Brown Stafford

    President and Chief Executive Officer, Director
    Robert A. Ingram

    Robert A. Ingram

    Chairman
    Show more

    Novan Office Locations

    Novan has an office in Durham
    Durham, NC, US
    4020 Stirrup Creek Dr #110
    Show all (2)

    Novan Financials and Metrics

    Summary Metrics

    Founding Date

    2008

    Novan Cybersecurity Score

    Cybersecurity ratingPremium dataset

    B

    85/100

    SecurityScorecard logo

    Novan Online and Social Media Presence

    Embed Graph

    Novan News and Updates

    Thinking about buying stock in Novan, Qualtrics International, BioNano Genomics, XL Fleet, or Atossa Therapeutics?

    NEW YORK, April 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, XM, BNGO, XL, and ATOS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

    Thinking about buying stock in Moderna, Nio, Pfizer, Novan, or Surface Oncology?

    NEW YORK, March 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, NIO, PFE, NOVN, and SURF. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

    Novan to Present at the H.C. Wainwright Global Life Sciences Conference

    MORRISVILLE, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-1…

    Novan Reports Full Year 2020 Financial Results and Provides Corporate Update

    – B-SIMPLE4 pivotal Phase 3 trial evaluating SB206 as a treatment for molluscum contagiosum progressing with top-line efficacy results targeted before the end of Q2 2021 –

    Thinking about buying stock in Ampio Pharmaceuticals, Motus GI, Phio Pharmaceuticals, Novan, or Oncolytics Biotech?

    NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMPE, MOTS, PHIO, NOVN, and ONCY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
    Show more

    Novan Blogs

    Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

    – Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating SB019 with berdazimer sodium as a potential intranasal therapy for COVID-19, with results targeted

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology Content Import Thu, 04/22/2021 - 09:01 Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology April 22, 2021 at 9:01 AM EDT Thi…

    Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors

    – Recognized healthcare and life science industry leader with over 35 years of international product development, strategy and commercialization experience – MORRISVILLE, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the election of

    Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

    MORRISVILLE, N.C., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement for

    Novan Frequently Asked Questions

    • When was Novan founded?

      Novan was founded in 2008.

    • Who are Novan key executives?

      Novan's key executives are Carri Geer, John M. Gay and W. Kent Geer.

    • How many employees does Novan have?

      Novan has 41 employees.

    • Who are Novan competitors?

      Competitors of Novan include Altis Biosystems, Accellix and Arc Bio.

    • Where are Novan offices?

      Novan has an office in Durham.

    • How many offices does Novan have?

      Novan has 2 offices.